We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current A1LN34 market cap is 5.39B. The company's latest EPS is USD -3.5081 and P/E is -45.72.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 319.29M | 318.75M | 750.53M | 439.72M | 494.33M |
| Operating Income | -149.81M | -229.83M | 213.87M | -116.4M | -43.44M |
| Net Income | -174.1M | -276.02M | 147.75M | -137.87M | -65.94M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B |
| Operating Income | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M |
| Net Income | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.39B | 3.4B | 3.84B | 3.83B | 3.82B |
| Total Liabilities | 3.65B | 3.81B | 4B | 4.05B | 4.04B |
| Total Equity | -259.24M | -408.13M | -165.87M | -220.64M | -219.27M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.4B | 3.41B | 3.64B | 3.55B | 3.83B |
| Total Liabilities | 956.44M | 2.39B | 3.06B | 3.7B | 4.05B |
| Total Equity | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -166.48M | -225.46M | 133.95M | 104.16M | -81.52M |
| Investing | -76.22M | -84.93M | -95.69M | -336.35M | -67.62M |
| Financing | 46.37M | 99.77M | 132.9M | 172.13M | 28.91M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M |
| Investing | -417.68M | -435.52M | -273.3M | 169.35M | -336.35M |
| Financing | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M |
| Market Cap | 5.39B |
| Price to Earnings Ratio | -45.72 |
| Price to Sales Ratio | 11.01 |
| Price to Cash Ratio | 24.77 |
| Price to Book Ratio | -91.22 |
| Dividend Yield | - |
| Shares Outstanding | 125.49M |
| Average Volume (1 week) | 14 |
| Average Volume (1 Month) | 10 |
| 52 Week Change | -7.91% |
| 52 Week High | 51.52 |
| 52 Week Low | 36.23 |
| Spread (Intraday) | 8.52 (19.09%) |
| Company Name | Alnylam Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alnylam.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
